NCCN Guidelines Insights: Rectal Cancer, Version 6.2020

Featured Updates to the NCCN Guidelines

View More View Less
  • 1 Robert H. Lurie Comprehensive Cancer Center of Northwestern University;
  • 2 UCSF Helen Diller Family Comprehensive Cancer Center;
  • 3 University of Michigan Rogel Cancer Center;
  • 4 City of Hope National Medical Center;
  • 5 Vanderbilt-Ingram Cancer Center;
  • 6 Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;
  • 7 Fox Chase Cancer Center;
  • 8 University of Wisconsin Carbone Cancer Center;
  • 9 Huntsman Cancer Institute at the University of Utah;
  • 10 Fred & Pamela Buffett Cancer Center;
  • 11 O’Neal Comprehensive Cancer Center at UAB;
  • 12 Moffitt Cancer Center;
  • 13 Mayo Clinic Cancer Center;
  • 14 Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;
  • 15 Stanford Cancer Institute;
  • 16 Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;
  • 17 University of Colorado Cancer Center;
  • 18 Dana-Farber/Brigham and Women’s Cancer Center;
  • 19 The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;
  • 20 Roswell Park Comprehensive Cancer Center;
  • 21 The University of Texas MD Anderson Cancer Center;
  • 22 Massachusetts General Hospital Cancer Center;
  • 23 UC San Diego Moores Cancer Center;
  • 24 Memorial Sloan Kettering Cancer Center;
  • 25 Abramson Cancer Center at the University of Pennsylvania;
  • 26 The University of Tennessee Health Science Center;
  • 27 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;
  • 28 Duke Cancer Institute; and
  • 29 National Comprehensive Cancer Network.
Restricted access

The NCCN Guidelines for Rectal Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with rectal cancer. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines. These updates include clarifying the definition of rectum and differentiating the rectum from the sigmoid colon; the total neoadjuvant therapy approach for localized rectal cancer; and biomarker-targeted therapy for metastatic colorectal cancer, with a focus on new treatment options for patients with BRAF V600E– or HER2 amplification–positive disease.

  • 1.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:730.

  • 2.

    Cheng L, Eng C, Nieman LZ, . Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005. Am J Clin Oncol 2011;34:573580.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Siegel R, Ward E, Brawley O, . Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212236.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Siegel RL, Miller KD, Goding Sauer A, . Colorectal cancer statistics, 2020. CA Cancer J Clin 2020;70:730.

  • 5.

    Baxter NN, Garcia-Aguilar J. Organ preservation for rectal cancer. J Clin Oncol 2007;25:10141020.

  • 6.

    Rajput A, Bullard Dunn K. Surgical management of rectal cancer. Semin Oncol 2007;34:241249.

  • 7.

    Weiser MR, Landmann RG, Wong WD, . Surgical salvage of recurrent rectal cancer after transanal excision. Dis Colon Rectum 2005;48:11691175.

  • 8.

    Wiig JN, Larsen SG, Giercksky KE. Operative treatment of locally recurrent rectal cancer. Recent Results Cancer Res 2005;165:136147.

  • 9.

    Morino M, Risio M, Bach S, . Early rectal cancer: the European Association for Endoscopic Surgery (EAES) clinical consensus conference. Surg Endosc 2015;29:755773.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Cirocchi R, Trastulli S, Abraha I, . Non-resection versus resection for an asymptomatic primary tumour in patients with unresectable stage IV colorectal cancer. Cochrane Database Syst Rev 2012;8:CD008997.

    • Search Google Scholar
    • Export Citation
  • 11.

    Nelson H, Petrelli N, Carlin A, . Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst 2001;93:583596.

  • 12.

    Pilipshen SJ, Heilweil M, Quan SH, . Patterns of pelvic recurrence following definitive resections of rectal cancer. Cancer 1984;53:13541362.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Revelli M, Paparo F, Bacigalupo L, . Comparison of computed tomography and magnetic resonance imaging in the discrimination of intraperitoneal and extraperitoneal rectal cancer: initial experience. Clin Imaging 2016;40:5762.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Gollub MJ, Maas M, Weiser M, . Recognition of the anterior peritoneal reflection at rectal MRI. AJR Am J Roentgenol 2013;200:97101.

  • 15.

    DʼSouza N, de Neree Tot Babberich MPM, d’Hoore A, . Definition of the rectum: an international, expert-based Delphi consensus. Ann Surg 2019;270:955959.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Cercek A, Goodman KA, Hajj C, . Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer. J Natl Compr Canc Netw 2014;12:513519.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Chau I, Brown G, Cunningham D, . Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 2006;24:668674.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Fernández-Martos C, Pericay C, Aparicio J, . Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo Cancer de Recto 3 study. J Clin Oncol 2010;28:859865.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Perez K, Safran H, Sikov W, . Complete neoadjuvant treatment of rectal cancer: the Brown University Oncology Group CONTRE study. Am J Clin Oncol 2017;40:283287.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Maréchal R, Vos B, Polus M, . Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study. Ann Oncol 2012;23:15251530.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Nogué M, Salud A, Vicente P, . Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study. Oncologist 2011;16:614620.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Fernandez-Martos C, Garcia-Albeniz X, Pericay C, . Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial. Ann Oncol 2015;26:17221728.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Sclafani F, Brown G, Cunningham D, . PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer. Ann Oncol 2016;27:15571565.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Cercek A, Roxburgh CSD, Strombom P, . Adoption of total neoadjuvant therapy for locally advanced rectal cancer. JAMA Oncol 2018;4:e180071.

  • 25.

    Gatalica Z, Xiu J, Swensen J, . Molecular characterization of cancers with NTRK gene fusions. Mod Pathol 2019;32:147153.

  • 26.

    Okamura R, Boichard A, Kato S, . Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: implications for NTRK-targeted therapeutics. JCO Precis Oncol 2018;2018:10.1200/PO.18.00183.

  • 27.

    Cocco E, Benhamida J, Middha S, . Colorectal carcinomas containing hypermethylated MLH1 promoter and wild-type BRAF/KRAS are enriched for targetable kinase fusions. Cancer Res 2019;79:10471053.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Rozlytrek [package insert]. South San Francisco, CA: Genentech, Inc.; 2019.

  • 29.

    Vitrakvi [package insert]. Stamford, CT: Loxo Oncology, Inc.; 2018.

  • 30.

    Drilon A, Laetsch TW, Kummar S, . Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018;378:731739.

  • 31.

    Doebele RC, Drilon A, Paz-Ares L, . Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 2020;21:271282.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Tol J, Nagtegaal ID, Punt CJA. BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009;361:9899.

  • 33.

    Van Cutsem E, Köhne CH, Láng I, . Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29:20112019.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 34.

    Maughan TS, Adams RA, Smith CG, . Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011;377:21032114.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35.

    Kopetz S, McDonough SL, Lenz HJ, . Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406) [abstract]. J Clin Oncol 2017;35(Suppl):Abstract 3505.

    • Search Google Scholar
    • Export Citation
  • 36.

    Corcoran RB, André T, Atreya CE, . Combined BRAF, EGFR, and MEK inhibition in patients with BRAFV600E-mutant colorectal cancer. Cancer Discov 2018;8:428443.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Kopetz S, Grothey A, Cutsem EV, . BEACON CRC: a randomized, 3-arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E–mutant metastatic colorectal cancer [abstract]. Ann Oncol 2019;30:iv154.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 38.

    Van Cutsem E, Huijberts S, Grothey A, . Binimetinib, encorafenib, and cetuximab triplet therapy for patients with BRAF V600E-mutant metastatic colorectal cancer: safety lead-in results from the phase III BEACON Colorectal Cancer study. J Clin Oncol 2019;37:14601469.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 39.

    Kopetz S, Grothey A, Yaeger R, . Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med 2019;381:16321643.

  • 40.

    Kopetz S, Grothey A, Cutsem EV, . Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC) [abstract]. J Clin Oncol 2020;38(Suppl):Abstract 8.

    • Search Google Scholar
    • Export Citation
  • 41.

    Sartore-Bianchi A, Trusolino L, Martino C, . Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol 2016;17:738746.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Raghav KPS, Overman MJ, Yu R, . HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer [abstract]. J Clin Oncol 2016;34(Suppl):Abstract 3517.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 43.

    Sartore-Bianchi A, Amatu A, Porcu L, . HER2 positivity predicts unresponsiveness to EGFR-targeted treatment in metastatic colorectal cancer. Oncologist 2019;24:13951402.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44.

    Herzuma [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc; 2019.

  • 45.

    Kanjinti [package insert]. Thousand Oaks, CA: Amgen Inc.; 2019.

  • 46.

    Ogivri [package insert]. Steinhausen, Switzerland: Mylan GmbH; 2019.

  • 47.

    Ontruzant [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp; 2019.

  • 48.

    Trazimera [package insert]. New York, NY: Pfizer Inc; 2019.

  • 49.

    Meric-Bernstam F, Hurwitz H, Raghav KPS, . Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol 2019;20:518530.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1204 1204 553
PDF Downloads 504 504 244
EPUB Downloads 0 0 0